Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.

This review discusses how transposable element activation may hinder tissue regeneration and explores mechanisms to control this activity, reporting no new experimental results.

This study found that dermatologists in São Paulo reported increased confidence in teledermatology over one year, citing its utility for triage and diagnosis, particularly for superficial infections and pigmentary disorders.

This study found that among adults with severe alopecia areata, alopecia totalis, or alopecia universalis, oral tofacitinib was more effective than methotrexate in reducing hair loss over a 12-week period, though long-term safety and efficacy remain unestablished.

This study found that tofacitinib and baricitinib had an acceptable adverse reaction profile when used to treat rheumatoid arthritis, with similar side effects to those described in their technical data sheets.

TEC kinases may help cause inflammation in vitiligo and could be targeted for treatment.

This study emphasizes the need for a formal evaluation of direct-to-consumer telemedicine services in Australia to ensure safety, privacy, and ethical standards while maintaining high-quality healthcare.

In this study, pediatric patients who underwent tissue expansion surgery reported varying quality-of-life outcomes, with a median score of +17, and most would recommend the procedure despite some negative experiences, indicating the need for further research to understand factors influencing these outcomes.

This review discusses the potential of small extracellular vesicles (sEVs) as next-generation therapeutics, noting their ability to overcome biological barriers and modulate cellular environments for various diseases.

In this case report, researchers identified a potential adverse skin reaction, called SDRIFE or Baboon syndrome, caused by the drug tofacitinib in a 19-year-old woman being treated for alopecia subtotalis, leading the authors to recommend discontinuation of the drug.

This study found that tofacitinib may be effective for treating pediatric rheumatic diseases, with especially promising results in patients with autoinflammatory diseases, arthritis and alopecia, and juvenile dermatomyositis.

This report describes a boy with ectodermal dysplasias who was genetically diagnosed due to newly discovered TSPEAR gene variants, which have now been associated with this condition.

This study found that prolonged tofacitinib treatment in adult Indian patients with moderate-to-severe alopecia areata was associated with a high regrowth rate, which varied with factors like age at disease onset and treatment duration.

Tofacitinib might be used to treat hair loss.

In this study, a 5% black tea extract hair tonic showed hair growth-promoting activity in rabbits, achieving 9.62 mm growth by day 18, with all tested formulas proving physically stable.

In a mouse model of chemotherapy-induced alopecia, this study found that enhancing ETV2 expression improved angiogenesis and hair regrowth following 5-fluorouracil treatment.

This article discusses the development and clinical progress of PROTAC technology, particularly focusing on the New Drug Application for vepdegestrant, an estrogen receptor-targeting PROTAC, marking significant advancements in targeted protein degradation therapies.

This study evaluated green tea extract-loaded spanlastic formulations and found that a vesicle builder to edge activator ratio of 8:2 produced optimal characteristics, including a particle size of 419.70 nm, an entrapment efficiency of 60.85%, and a drug loading of 11.07%.

This essay reviews issues related to telogen effluvium, including diagnosis, classification, and management, but it reports no new clinical findings.

The researchers reported that the ethyl ester group in YH239-EE may enhance its ability to induce cell death, making the (+) enantiomer a potentially promising therapy for breast cancer reflected in MCF7 cell studies.

This letter to the editor on postpartum telogen effluvium does not include new research findings or data.

This review discusses telogen effluvium, a common type of hair loss, focusing on differentiation from other conditions and potential causes, but presents no new research findings.

A vitamin and mineral supplement significantly reduced hair shedding in Brazilian women with telogen effluvium.

This review summarizes findings on the long-term use of tofacitinib for severe alopecia areata, reporting its potential as a promising treatment option.

This review discusses the various triggers and diagnostic challenges in determining the cause of telogen effluvium-related hair loss, without providing new clinical results.

This study observed distinct post-marketing safety signal patterns for baricitinib and tofacitinib in adult AA, influenced by their differing regulatory uses and real-world contexts, and emphasizes the need for future studies to validate these findings.

This review discusses telogen effluvium as a common cause of diffuse hair loss and reports no new clinical results, noting diagnostic and treatment challenges.

This review discusses telogen effluvium, a common form of hair loss, and reports no new clinical results; the authors outline possible causes, typical prognosis, and management strategies.

This study found that using urine tenofovir monitoring for PrEP adherence is well-accepted and may help overcome adherence barriers among participants at a U.S. urban clinical center.

This report examines the cautious approach to administering live vaccines to an infant with a heterozygous FOXN1 variant, noting the importance of monitoring TREC levels and immune function indicators in guiding vaccination decisions in such cases.